Research Article
Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?
Table 2
Distribution of cases in the study.
| | | Benign (%) | Borderline (%) | Malignant (%) | Total (%) |
| | Histopathology | 237 (84.3) | 7 (2.5) | 37 (13.2) | 281 |
| | Age (years) | | | | | | ≤20 | 24 (8.5) | 1 (0.3) | 2 (0.7) | 27 (9.6) | | 20–39 | 139 (49.4) | 3 (1.0) | 4 (1.4) | 146 (51.9) | | 40–59 | 60 (21.3) | 3 (1.0) | 21 (7.4) | 84 (29.8) | | ≥60 | 14 (4.9) | 0 (0) | 10 (3.5) | 24 (8.5) |
| | Premenopausal | 203 (72.2) | 6 (2.1) | 18 (6.4) | 227 (80.7) | | Postmenopausal | 34 (12.0) | 1 (0.3) | 19 (6.7) | 54 (19.2) |
| | Ultrasound score 1 | 196 (69.7) | 3 (1.0) | 8 (2.8) | 207 (73.6) | | Ultrasound score 3 | 41 (14.5) | 4 (1.4) | 29 (10.3) | 74 (26.3) |
| | CA125 ≥ 35 | 75 (26.6) | 4 (1.4) | 26 (9.2) | 105 (37.3) | | Ca125 < 35 | 162 (57.6) | 3 (1.0) | 11 (3.9) | 176 (62.6) |
| | RMI groups | | | | | | ≤25 | 117 (41.6) | 0 (0) | 3 (1.0) | 120 (42.7) | | 25.1–249.9 | 106 (37.7) | 5 (1.7) | 14 (4.9) | 125 (44.4) | | ≥250 | 14 (4.9) | 2 (0.7) | 20 (7.1) | 36 (12.8) |
|
|
